T‐DM1, an antibody–drug conjugate (ADC) incorporating DM1, has been acknowledged as the preferred second‐line treatment of HER2‐positive MBC and postneoadjuvant therapy for HER2‐positive early breast cancer, demonstrating remarkable and durable clinical efficacy.7, 8, 9. The gene discussed is ERBB2; the disease is breast carcinoma.